Early Screening and Diagnosis of CKD

Sponsor
Nanjing First Hospital, Nanjing Medical University (Other)
Overall Status
Recruiting
CT.gov ID
NCT02841371
Collaborator
(none)
1,000
1
173
5.8

Study Details

Study Description

Brief Summary

Chronic kidney disease (CKD) is a global public health problem. The prevalence of CKD in adults in China was 10.8%. Albuminuria measurement and estimating glomerular filtration rate (GFR) are the primary means of screening for CKD in epidemiological investigations. However, there are many important problems to be solved, whether albuminuria test or GFR evaluation. The investigators aim to detect thrice albumin-creatinine ratio (ACR) within three months, with simultaneous test of urinary protein-creatinine ratio (PCR), 24-hour urine protein excretion rate (PER) and 24-hour albumin albumin excretion rate (AER) to compare the effects of different times of screening for CKD and observe the daily physiological variation of ACR, PCR, AER and PER, derive ACR and PCR reference value on the basis of different genders, in order to facilitate the early diagnosis of CKD. Meanwhile, for more accurate assessment of GFR in Chinese populations, the investigators intend to validate beta-trace protein (BTP) based equation to evaluate GFR compared with 99mTc-diethylenetriamine pentaacetic acid (DTPA) renal clearance method. Then to develop GFR estimation equation based on the combination of serum creatinine, cystatin C, β2 -microglobulin and BTP applicable in China.

Condition or Disease Intervention/Treatment Phase
  • Radiation: 99mTc-DTPA

Detailed Description

Chronic kidney disease (CKD) is a global public health problem. The prevalence of CKD in adults in China was 10.8%. Awareness of CKD is only 10.04% from a national cross-sectional survey in China. CKD is characterised by decreased estimated glomerular filtration rate (eGFR) and increased albuminuria, present for more than three months, and is associated with adverse outcomes (all-cause mortality, acute kidney injury, and end-stage renal disease), independent of hypertension and diabetes, age, or sex. CKD may carry a coronary heart disease risk similar to that of diabetes. The estimated lifetime risk of CKD stage 3a was more than 50%, lower than that of hypertension (83%-90% for a 55-year-old), but higher than those for diabetes (33%-39%), coronary heart disease (32%-49% for a 40-year-old), and invasive cancer (38%-45%).

Albuminuria measurement and estimating glomerular filtration rate (GFR) are the primary means of screening for CKD in epidemiological investigations. However, there are many important problems to be solved, whether albuminuria test or GFR evaluation. The investigators aim to detect thrice albumin-creatinine ratio (ACR) within three months, with simultaneous test of urinary protein-creatinine ratio (PCR), 24-hour urine protein excretion rate (PER) and 24-hour albumin excretion rate (AER) to compare the effects of different times of screening for CKD and observe the daily physiological variation of ACR, PCR, AER and PER, and repeat test to reduce the physiological variation, and further derive ACR and PCR reference value on the basis of different genders, in order to facilitate the early diagnosis of CKD. Meanwhile, for more accurate assessment of GFR in Chinese populations, the investigators intend to validate beta-trace protein (BTP) based equation to evaluate GFR compared with 99mTc-diethylenetriamine pentaacetic acid (DTPA) renal clearance method. Then the investigators aim to develop GFR estimation equation based on the combination of serum creatinine, cystatin C, β2-microglobulin and BTP applicable in China, for early and accurate assessment of GFR in Chinese people, and develop appropriate software to estimating GFR.

Study Design

Study Type:
Observational
Anticipated Enrollment :
1000 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Early Screening and Diagnosis of Chronic Kidney Disease
Actual Study Start Date :
Aug 1, 2009
Anticipated Primary Completion Date :
Dec 31, 2022
Anticipated Study Completion Date :
Dec 31, 2023

Arms and Interventions

Arm Intervention/Treatment
chronic kidney disease (CKD)

chronic kidney disease (CKD) is defined as abnormalities of kidney structure (markers of kidney damage) or function (decreased GFR by 99mTc-DTPA renal clearance and/or eGFR), present for more than 3 months.

Radiation: 99mTc-DTPA
a 99mTc-DTPA renal dynamic imaging measurement as the reference glomerular filtration rate (rGFR).
Other Names:
  • technetium-99m-labeled diethylenetriaminepentaacetic acid
  • no CKD

    Suspected chronic kidney disease but no chronic kidney disease after screening by abnormalities of kidney structure (markers of kidney damage) or function (decreased GFR by 99mTc-DTPA renal clearance and/or eGFR), present for less than 3 months, or no abnormalities of kidney structure or function.

    Radiation: 99mTc-DTPA
    a 99mTc-DTPA renal dynamic imaging measurement as the reference glomerular filtration rate (rGFR).
    Other Names:
  • technetium-99m-labeled diethylenetriaminepentaacetic acid
  • Outcome Measures

    Primary Outcome Measures

    1. Bias of estimated GFR less than 5 ml per minute per 1.73 m2 versus reference GFR [1 year]

      Bias was defined as the median results of differences between estimated GFR and reference GFR (eGFR- rGFR).

    2. Precision of estimated GFR less than 30 ml per minute per 1.73 m2 versus reference GFR [1 year]

      Precision was defined as the interquartile range (IQR) of the differences between estimated GFR and reference GFR.

    3. Accuracy of estimated GFR more than 70% [1 year]

      Accuracy was calculated as the proportion of estimated GFR within 30% of reference GFR.

    Secondary Outcome Measures

    1. net reclassification index more than 10% [1 year]

      Net reclassification improvement (NRI) was defined as the sum of those classified upward to higher risk in those with an event plus those classified downward to lower risk in those without an event less the sum of those classified downward to lower risk in those with an event plus those classified to higher risk in those without an event. The event in this study was having a measured GFR that was less than 60 ml per minute per 1.73 m2.

    2. Composite outcomes of sensitivity of a single screen using estimated GFR and/or albuminuria to detect CKD more than 0.6, or specificity of a single screen using estimated GFR and/or albuminuria to detect CKD more than 0.8 [1 year]

      Sensitivity of a single screen using estimated GFR and/or albuminuria to detect CKD more than 0.6, or specificity of a single screen using estimated GFR and/or albuminuria to detect CKD more than 0.8

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 100 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Health examination population at the department of nephrology

    • Chronic kidney disease

    Exclusion Criteria:
    • Severe heart failure

    • Acute renal failure

    • Pleural or abdominal effusion

    • Serious edema or malnutrition

    • Skeletal muscle atrophy

    • Amputation

    • Ketoacidosis

    • Patients who were taking trimethoprim or cimetidine or angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blocker (ARB)

    • Patients who had recently received glucocorticoid and hemodialysis therapy

    • Female during the menstrual period

    • Pregnant woman

    • Who unable to sign informed consent

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Nanjing First Hospital, Nanjing Medical University Nanjing Jiangsu China 210006

    Sponsors and Collaborators

    • Nanjing First Hospital, Nanjing Medical University

    Investigators

    • Principal Investigator: Xin Du, Nanjing First Hospital, Nanjing Medical University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Nanjing First Hospital, Nanjing Medical University
    ClinicalTrials.gov Identifier:
    NCT02841371
    Other Study ID Numbers:
    • ES-CKD
    First Posted:
    Jul 22, 2016
    Last Update Posted:
    Apr 7, 2022
    Last Verified:
    Apr 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Keywords provided by Nanjing First Hospital, Nanjing Medical University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 7, 2022